Proving it can indeed beat deadlines when it wants to, the FDA issued a surprise approval of Seattle Genetics Inc.'s Adcetris (brentuximab vedotin) for two kinds of lymphoma late Friday afternoon – more than a week ahead of the Aug. 30 PDUFA date.